{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:32:30Z","timestamp":1765546350234},"reference-count":59,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2012.0466","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:20:04Z","timestamp":1525252804000},"source":"Crossref","is-referenced-by-count":4,"title":["Inpatient Treatment of Type 2 Diabetes"],"prefix":"10.3238","author":[{"given":"Thomas G. K.","family":"Breuer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juris J.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2012,6,29]]},"reference":[{"key":"10.3238\/arztebl.2012.0466_ref1","unstructured":"Heidemann C, Du Y, Scheidt-Nave C: Diabetes mellitus in Deutschland. Robert-Koch-Institut (ed.). Berlin 2011."},{"key":"10.3238\/arztebl.2012.0466_ref2","doi-asserted-by":"crossref","unstructured":"Siegel E: Medical care management of patients with diabetes mellitus in hospitals. The Ludwigshafen-Limburger diabetes model. Der Diabetologe 2008; 4: 20\u20139.","DOI":"10.1007\/s11428-007-0198-z"},{"key":"10.3238\/arztebl.2012.0466_ref3","doi-asserted-by":"crossref","unstructured":"American-Diabetes-Association: Standards of medical care in diabetes 2011. Diabetes Care 2011; 34 (Suppl 1): 11\u201361.","DOI":"10.2337\/dc11-S011"},{"key":"10.3238\/arztebl.2012.0466_ref4","doi-asserted-by":"crossref","unstructured":"Matthaei S, Bierwirth R, Fritsche A, et al.: Medikament\u00f6se antihyperglyk\u00e4mische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie. Diabetologie und Stoffwechsel 2009; 4: 32\u201364.","DOI":"10.1055\/s-0028-1098798"},{"key":"10.3238\/arztebl.2012.0466_ref5","unstructured":"Statistisches-Bundesamt: Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik). Diagnosen, Prozeduren, Fallpauschalen und Case Mix der vollstation\u00e4ren Patientinnen und Patienten in Krankenh\u00e4usern 2010."},{"key":"10.3238\/arztebl.2012.0466_ref6","doi-asserted-by":"crossref","unstructured":"Kunz R, Burnand B, Schunemann HJ: The GRADE System. An international approach to standardize the graduation of evidence and recommendations in guidelines. Internist 2008; 49: 673\u201380.","DOI":"10.1007\/s00108-008-2141-9"},{"key":"10.3238\/arztebl.2012.0466_ref7","unstructured":"Rote-Liste-Service-GmbH: Fachinformationsverzeichnis Deutschland. www.fachinfo.de."},{"key":"10.3238\/arztebl.2012.0466_ref8","doi-asserted-by":"crossref","unstructured":"Clement S, Braithwaite SS, Magee MF, et al.: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553\u201391.","DOI":"10.2337\/diacare.27.2.553"},{"key":"10.3238\/arztebl.2012.0466_ref9","unstructured":"Siegmund T: Insulintherapie unter besonderen Bedingungen. In: T Siegmund (ed.): Therapieregister Diabetes f\u00fcr die Klinik. Berlin, K\u00f6ln: Lehmanns Media GmbH 2011; 74\u201397."},{"key":"10.3238\/arztebl.2012.0466_ref10","doi-asserted-by":"crossref","unstructured":"Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765\u201372.","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"10.3238\/arztebl.2012.0466_ref11","doi-asserted-by":"crossref","unstructured":"Schernthaner G: Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010; 160: 8\u201319.","DOI":"10.1007\/s10354-010-0748-7"},{"key":"10.3238\/arztebl.2012.0466_ref12","doi-asserted-by":"crossref","unstructured":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"10.3238\/arztebl.2012.0466_ref13","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068\u201372.","DOI":"10.1161\/01.CIR.0000039105.49749.6F"},{"key":"10.3238\/arztebl.2012.0466_ref14","doi-asserted-by":"crossref","unstructured":"Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345\u201351.","DOI":"10.2337\/diacare.28.10.2345"},{"key":"10.3238\/arztebl.2012.0466_ref15","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale Versorgungsleitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter \u2013 Langfassung. Version 1.X. 2010. www.diabetes.versorgungsleitlinien.de."},{"key":"10.3238\/arztebl.2012.0466_ref16","unstructured":"Siegel E, Schr\u00f6der F, Kunder J, Dreyer M: Medikamente. In: Siegel E, Schr\u00f6der F, Kunder J, Dreyer M (eds.): Diabetes mellitus XXS pocket. Gr\u00fcnwald: B\u00f6rm Bruckmeiner Verlag GmbH 2011; 93\u2013116."},{"key":"10.3238\/arztebl.2012.0466_ref17","doi-asserted-by":"crossref","unstructured":"Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003; (2): CD002967.","DOI":"10.1002\/14651858.CD002967"},{"key":"10.3238\/arztebl.2012.0466_ref18","doi-asserted-by":"crossref","unstructured":"Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 1984; 27: 351\u20137.","DOI":"10.1007\/BF00304849"},{"key":"10.3238\/arztebl.2012.0466_ref19","doi-asserted-by":"crossref","unstructured":"Vogt C, Dreyhaupt J, Hasslacher C: Influence of declining kidney function on Insulin dosage in type 1- and type 2-diabetic patients. Diabetologie und Stoffwechsel 2006; 1: 311\u20138.","DOI":"10.1055\/s-2006-947260"},{"key":"10.3238\/arztebl.2012.0466_ref20","doi-asserted-by":"crossref","unstructured":"Umpierrez GE, Smiley D, Zisman A, et al.: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181\u20136.","DOI":"10.2337\/dc07-0295"},{"key":"10.3238\/arztebl.2012.0466_ref21","doi-asserted-by":"crossref","unstructured":"Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073\u201384.","DOI":"10.1016\/S0140-6736(08)60485-7"},{"key":"10.3238\/arztebl.2012.0466_ref22","doi-asserted-by":"crossref","unstructured":"Holman RR, Farmer AJ, Davies MJ, et al.: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736\u201347.","DOI":"10.1056\/NEJMoa0905479"},{"key":"10.3238\/arztebl.2012.0466_ref23","doi-asserted-by":"crossref","unstructured":"Umpierrez GE, Hor T, Smiley D, et al.: Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 564\u20139.","DOI":"10.1210\/jc.2008-1441"},{"key":"10.3238\/arztebl.2012.0466_ref24","doi-asserted-by":"crossref","unstructured":"Goldberg PA, Siegel MD, Sherwin RS, et al.: Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461\u20137.","DOI":"10.2337\/diacare.27.2.461"},{"key":"10.3238\/arztebl.2012.0466_ref25","unstructured":"European Commission: Commission Implementing Decision of 22.11.2011 amending the marketing authorisation granted by Decision C (2007)1362 for \u201eJanuvia \u2013 Sitagliptin\u201c, a medicinal product for human use. 2011."},{"key":"10.3238\/arztebl.2012.0466_ref26","doi-asserted-by":"crossref","unstructured":"Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359\u201367.","DOI":"10.1056\/NEJMoa011300"},{"key":"10.3238\/arztebl.2012.0466_ref27","doi-asserted-by":"crossref","unstructured":"Finfer S, Chittock DR, Su SY, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283\u201397.","DOI":"10.1056\/NEJMoa0810625"},{"key":"10.3238\/arztebl.2012.0466_ref28","doi-asserted-by":"crossref","unstructured":"Van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449\u201361.","DOI":"10.1056\/NEJMoa052521"},{"key":"10.3238\/arztebl.2012.0466_ref29","doi-asserted-by":"crossref","unstructured":"Inzucchi SE: Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355: 1903\u201311.","DOI":"10.1056\/NEJMcp060094"},{"key":"10.3238\/arztebl.2012.0466_ref30","doi-asserted-by":"crossref","unstructured":"Trence DL, Kelly JL, Hirsch IB: The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 2003; 88: 2430\u20137.","DOI":"10.1210\/jc.2003-030347"},{"key":"10.3238\/arztebl.2012.0466_ref31","doi-asserted-by":"crossref","unstructured":"Zander JF, Risse A: Perioperative Behandlung und Einstellung des Diabetes mellitus. Orthop\u00e4de 2009; 38: 818\u2013827.","DOI":"10.1007\/s00132-009-1452-4"},{"key":"10.3238\/arztebl.2012.0466_ref32","unstructured":"Mehnert F, Mehnert B, Pereira PL, Clausen CD, H\u00e4ring HU: Metformin und intraven\u00f6se R\u00f6ntgenkontrastmittel: Ein Risiko? Diabetes und Stoffwechsel 2000; 9: 235\u20138."},{"key":"10.3238\/arztebl.2012.0466_ref33","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.3238\/arztebl.2012.0466_ref34","unstructured":"Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl 2): B21\u20139."},{"key":"10.3238\/arztebl.2012.0466_ref35","doi-asserted-by":"crossref","unstructured":"Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"key":"10.3238\/arztebl.2012.0466_ref36","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545\u201359.","DOI":"10.1056\/NEJMoa0802743"},{"key":"10.3238\/arztebl.2012.0466_ref37","doi-asserted-by":"crossref","unstructured":"Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129\u201339.","DOI":"10.1056\/NEJMoa0808431"},{"key":"10.3238\/arztebl.2012.0466_ref38","doi-asserted-by":"crossref","unstructured":"Bell DS: Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 185\u20136.","DOI":"10.1503\/cmaj.051237"},{"key":"10.3238\/arztebl.2012.0466_ref39","doi-asserted-by":"crossref","unstructured":"Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9\u201312.","DOI":"10.1136\/heart.90.1.9"},{"key":"10.3238\/arztebl.2012.0466_ref40","doi-asserted-by":"crossref","unstructured":"Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S: Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 (Suppl 2): 223\u201331.","DOI":"10.2337\/dc09-S315"},{"key":"10.3238\/arztebl.2012.0466_ref41","doi-asserted-by":"crossref","unstructured":"Williams-Herman D, Engel SS, Round E, et al.: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2008; 10: 7.","DOI":"10.1186\/1472-6823-10-7"},{"key":"10.3238\/arztebl.2012.0466_ref42","doi-asserted-by":"crossref","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962\u20135.","DOI":"10.1161\/01.CIR.0000120505.91348.58"},{"key":"10.3238\/arztebl.2012.0466_ref43","doi-asserted-by":"crossref","unstructured":"Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP: DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3: 195\u2013201.","DOI":"10.1161\/CIRCIMAGING.109.899377"},{"key":"10.3238\/arztebl.2012.0466_ref44","unstructured":"Mamas MA, Neyses L, Fath-Ordoubadi F: A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol 2010; 15: e20\u20134."},{"key":"10.3238\/arztebl.2012.0466_ref45","doi-asserted-by":"crossref","unstructured":"Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166\u201376.","DOI":"10.1093\/eurheartj\/ehm518"},{"key":"10.3238\/arztebl.2012.0466_ref46","doi-asserted-by":"crossref","unstructured":"Futh R, Dinh W, Bansemir L, et al.: Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure? Acta Diabetol 2009; 46: 335\u20138.","DOI":"10.1007\/s00592-009-0105-8"},{"key":"10.3238\/arztebl.2012.0466_ref47","doi-asserted-by":"crossref","unstructured":"Tzoulaki I, Molokhia M, Curcin V, et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.","DOI":"10.1136\/bmj.b4731"},{"key":"10.3238\/arztebl.2012.0466_ref48","doi-asserted-by":"crossref","unstructured":"Bennett WL, Maruthur NM, Singh S, et al.: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602\u201313.","DOI":"10.7326\/0003-4819-154-9-201105030-00336"},{"key":"10.3238\/arztebl.2012.0466_ref49","unstructured":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): 1\u2013266."},{"key":"10.3238\/arztebl.2012.0466_ref50","doi-asserted-by":"crossref","unstructured":"Holstein A, Stumvoll M: Contraindications can damage your health\u2013is metformin a case in point? Diabetologia 2005; 48: 2454\u20139.","DOI":"10.1007\/s00125-005-0026-1"},{"key":"10.3238\/arztebl.2012.0466_ref51","doi-asserted-by":"crossref","unstructured":"Nowicki M, Rychlik I, Haller H, et al.: Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230\u20139.","DOI":"10.1111\/j.1742-1241.2011.02812.x"},{"key":"10.3238\/arztebl.2012.0466_ref52","doi-asserted-by":"crossref","unstructured":"Hasslacher C, Vogt C, Raupp D, Dreyhaupt J: Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin. Dtsch Med Wochenschr 2007; 132: 2500\u20134.","DOI":"10.1055\/s-2007-993090"},{"key":"10.3238\/arztebl.2012.0466_ref53","doi-asserted-by":"crossref","unstructured":"Kutoh E: Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother 2005; 3: 270\u20133.","DOI":"10.1016\/j.amjopharm.2005.12.002"},{"key":"10.3238\/arztebl.2012.0466_ref54","doi-asserted-by":"crossref","unstructured":"Ahmed MH, Byrne CD: Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009; 11: 188\u201395.","DOI":"10.1111\/j.1463-1326.2008.00926.x"},{"key":"10.3238\/arztebl.2012.0466_ref55","doi-asserted-by":"crossref","unstructured":"Garinis GA, Fruci B, Mazza A, et al.: Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010; 34: 1255\u201364.","DOI":"10.1038\/ijo.2010.40"},{"key":"10.3238\/arztebl.2012.0466_ref56","doi-asserted-by":"crossref","unstructured":"Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893\u20134.","DOI":"10.1016\/S0140-6736(01)06042-1"},{"key":"10.3238\/arztebl.2012.0466_ref57","doi-asserted-by":"crossref","unstructured":"Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K: Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009; 10: 5\u201313.","DOI":"10.1111\/j.1399-5448.2008.00450.x"},{"key":"10.3238\/arztebl.2012.0466_ref58","unstructured":"Migoya EM, Stevens CH, Bergman AJ, et al.: Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16: e165\u201370."},{"key":"10.3238\/arztebl.2012.0466_ref59","doi-asserted-by":"crossref","unstructured":"Nielsen LL, Okerson T, Holcombe J, Hoogwerf B: Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2: 255\u201360.","DOI":"10.1177\/193229680800200214"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2012.0466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:45:20Z","timestamp":1638870320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2012.0466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,29]]},"references-count":59,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2012.0466","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,29]]}}}